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Abstract
Bacground/Aim. Using omega-3 polyunsaturated fatty
acids (PUFAs) in coronary artery bypass graft surgery
(CABG) could provide protection against ischemic-
reperfusion damage, prevention of postoperative arrhyth-
mia and attenuation of inflammatory response. However,
omega-3 PUFAs inhibit cyclooxygenase (and thus decrease
the synthesis of thromboxane A2 from arachidonic acid in
platelets), which leads to decreased platelet aggregation. In
cardiac surgery it is necessary to achieve a balance between
inhibition and full platelets function. It is as well as im-
portant to closely follow hematological parameters, im-
paired by CABG itself. Therefore, the aim of the study
was to establish the effects of pretreatment with omega-
PUFAs on hematological parameters and plateletes aggre-
gation in patients with elective CABG. Methods. This
prospective, randomized, placebo-controlled, single-center
trial was performed on parallel groups. The patients (n =
40) undergoing elective CABG were randomized receiving
preoperative intravenous omega-3 PUFAs (Omegaven
®
10%) infusion (the PUFAs group) or the same volume of
0.9% saline solution infusion (the control group). Infusion
was given a day before surgery and repeated four hours
before starting extracorporeal circulation (CPB) via the pe-
ripheral vein at single doses of 100 mL (25 mL/h). Platelet
function analysis was performed using multiple electrode
aggregometry (MEA, multiplate-analyzer) before starting
CPB and 2 h postoperatively for the patients of both
groups. Results. There were no clinically relevant differ-
ences in baseline characteristics between the groups. He-
matological parameters were not significantly different
between the groups pre-, intra- and postoperatively. Dur-
ing the first 24 h after surgery, the loss of blood was simi-
lar in the PUFAs and the control group (680 ± 274 mL
and 608 ± 210 mL, respectively; p = 0.356). Postopera-
tively, platelet aggregation was not significantly different
between the PUFAs and the control group in adenosine
diphosphate (ADP) test (39 ± 11 and 42 ± 15, respec-
tively; p = 0.701), arachidonic acid (ASPI) test (64 ± 24
and 70 ± 27, respectively;  p = 0.525) and trombin recep-
tor-activating peptide (TRAP) test (68 ± 25 and 75 ± 26,
respectively; p = 0.396), while their aggregation in collagen
(COL) test was statistically significantly lower in the PU-
FAs related to the control group (32 ± 15 and 47 ± 20, re-
spectively;  p = 0.009). Conclusion. Acute pretreatment
with omega-3 PUFAs insignificantly affected the activity
of platelets and did not influence postoperative blood loss.
Key words:
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Apstrakt
Uvod/Cilj. Primenom omega-3 polinezasiýenih masnih ki-
selina (PUFAs – polyunsaturated fattly acids) kod kardiohirur-
ških operacija može se postiýi zaštita od ishemijsko-
reperfuzionih ošteýenja, prevencija postoperativnih aritmija
i smanjenje inflamatornog odgovora. MeĀutim, omega-3
PUFAs inhibiraju ciklooksigenazu (ovo smanjuje sintezu
tromboksana A2 iz arahidonske kiseline u trombocitima),
što smanjuje agregaciju trombocita. Kod kardiohirurških
operacija neophodno je postiýi ravnotežu izmeĀu inhibicije i
pune funkcije trombocita. TakoĀe, važno je pratiti hemato-Volumen 70, Broj 4 VOJNOSANITETSKI PREGLED Strana 397
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loške parametre koji su poremeýeni samom hirurškom in-
tervencijom. Cilj ove studije bio je da se utvrde efekte preo-
perativne infuzije omega-3 PUFAs na hematološke para-
metre i agregaciju trombocita kod bolesnika koji su podvrg-
nuti elektivnoj revaskularizaciji miokarda. Metode. Ova
prospektivna, randomizovana, placebom kontrolisana studija
vršena je na paralelnim grupama. Bolesnici (n = 40) planirani
za elektivni hirurški zahvat revaskularizacije miokarda primali
su infuziju omega-3 PUFAs (Omegaven
® 10%) ili istu koliÿi-
nu 0,9% NaCl, po 100 mL (25 mL/h)/dan pre hirurške in-
tervencije i ÿetiri sata pre poÿetka vantelesnog krvotoka. Ana-
liza funkcije trombocita u obe grupe vršena je metodom mul-
tiple electrode aggregometry (MEA) pre poÿetka vantelesnog kr-
votoka i dva sata nakon završetka intervencije. Rezultati.
Nije bilo znaÿajne razlike u vrednostima hematoloških pa-
rametara izmeĀu grupa, pre-, intra- i postoperativno. To-
kom 24 sata postoperativno, gubitak krvi bio je sliÿan u
grupi koja je primala omega-3 PUFA i kontrolnoj grupi koja
je primala placebo (680 ± 274 mL i 608 ± 210 mL, respek-
tivno;  p = 0,356). Postoperativo, nije postojala statistiÿki
znaÿajna razlika u agregaciji trombocita izmeĀu grupe koja
je primala omega-3 PUFA i u kontrolnoj grupi koja je pri-
mala placebo u adenozin difosfat (ADP) testu (39 ± 11 i 42
± 15, respektivno; p = 0,701), ASPI testu (64 ± 24 i 70 ±
27; respektivno; p = 0,525) i trombin receptor-aktivirajuýi
peptid (TRAP) testu (68 ± 25 i 75 ± 26, respektivno; p =
0,396). Agregacija u kolagen (COL) testu bila je statistiÿki
znaÿajno manja u grupi koja je primala omega-3 PUFA u
odnosu na kontrolnu grupu (32 ± 14 i 47 ± 20, respektivno;
p = 0,009). Zakljuÿak. Preoperativna primena omega-3
PUFAs jednako utiÿe na agregaciju trombocita, kao i place-
bo u kontrolnoj grupi, osim kod COL testa ÿije su vrednosti
statistiÿki znaÿajno niže u grupi tretiranoj omega-3 PUFAs u
odnosu na kontrolnu grupu, ali to ne utiÿe na postoperativ-
ne gubitke krvi.
Kljuÿne reÿi:
masne kiseline, omega-3; aortokoronarno
premošýavanje; trombociti, agregacija; hematološki
testovi; krvarenje.
Introduction
Bleeding is a common complication of cardiac surgery
with cardiopulmonary bypass (CPB), which can require
transfusion of blood products 
1–3 and in 3% ± 6% of cases
mediastinal re-exploration 
4. Among causes of excessive
bleeding, platelet dysfunction is considered to be the most
important in the early postoperative period. During coro-
nary artery bypass graft (CABG) surgery there is the oppo-
sition between the benefit of platelet inhibition to reduce
the risk of pre-operative infarction and postoperative occlu-
sion of anastomosed coronary arteries, and the need to
maintain full platelet function for optimal hemostasis in
surgical incisions.
Previous studies have demonstrated beneficial effects of
omega-3 polyunsaturated fatty acids (PUFAs), eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA) in platelet
functions 
5. Whereas the predominant product of arachidonic
acid (AA) in platelets, thromboxane A2 (TXA2) is a platelet
agonist, the corresponding product of EPA, thromboxane A3
(TXA3), is virtually biologically inert. In contrast, both
prostaglandin I2 derived from AA, and prostaglandin I3 de-
rived from EPA, are potent vasodilators and platelet inhibi-
tors 
6. Supplementation of omega-3 PUFAs resulted in a shift
towards the production of more favorable eicosanoids that
inhibit platelet aggregability 
7.
Omega-3 PUFAs are commonly considered to have an-
tithrombotic effects, based on increased bleeding times at
very high doses (e.g. 15 g/day) 
8. Conversely, in human tri-
als, omega-3 PUFA consumption has no consistent effects on
platelet aggregation or coagulation factors 
9, 10. No excess
clinical bleeding risk has been seen in randomized clinical
trials of fish or fish oil consumption, including people under-
going surgery or percutaneous intervention and/or also tak-
ing aspirin or warfarin 
8, 11.
We have recently shown that preoperative administra-
tion of omega-3 PUFAs has cardioprotective effect in pa-
tients with CPB manifested in increased oxygen extraction
and lactate uptake with simultaneous decrease of serum tro-
ponin I and creatinin kinase myocardial band (MB) levels 
12.
In the frame of the same study, we followed the effect of
omega-3 PUFAs on their influence on postsurgical patients
platelet aggregation. According to the previous findings of
the other authors 
11, 13 that omega-3 PUFAs do not affect
bleeding in the same or similar categories of patients we as-
sumed that they will not provoke bleeding surpassing the risk
expected in the control group of patients.
The aim of the study was to establish the relationship
between hematological parameters and the activity of plate-
letes in patients with elective CABG pretreated by 3-omega
PUFAs.
Methods
This prospective, randomized, placebo-controlled study
was performed on parallel groups. Study enrollment occurred
between August 2010 and September 2011. The study proto-
col was approved by the Ethical Committee of Military
Medical Academy, and all the patients gave written informed
consent.
Forty patients scheduled to undergo their first on-pump
CABG surgery were included in the study. For recruitment,
patients needed to be older than 18 years of age, in normal
sinus rhythm, and in stable hemodynamic conditions before
surgery. Patients were excluded in cases of emergency
CABG, redo CABG, combined CABG and any other cardiac
procedure, Q-wave myocardial infarction in the last six
weeks, unstable angina, or poor left ventricular function,
those with abnormal coagulation tests, including a history of
coagulopathy and preoperative treatment with other antico-
agulants. All the participants denied the intake of any anti-
agregation medication during the previous five days. All the
patients were treated by the same surgical and anesthesiolo-
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Eligible patients were assigned to one of the two study
arms according to a computer-generated randomization list:
the control (placebo) group (usual care), and the usual care
plus PUFAs group.
The PUFAs infusion consisted of 100 mL of a lipid
emulsion with a high content of omega-3 PUFAs (Omegaven
®
10%, Fresenius Kabi, Bad Homburg, Germany). The same
batch of Omegaven
® was used throughout the study, and 100
mL of the lipid emulsion contained 1.25–2.82 g of EPA and
1.44–3.09 of DHA. Infusion was given a day before surgery
and repeated 4 h before starting CPB via the peripheral vein at
single doses of 100 mL (25 mL/h). The patients in the control
group received an equal volume of 0.9% saline.
Preoperative sedation with 5 mg of intramuscular mida-
zolam was administered to patients on call to the operating
room. All the patients received prophylactic preoperative an-
tibiotics (cefazolin 2 g preincision, and 2 g post-CPB; or if
allergic to penicillin, vancomycin 1 g preincision and 500 mg
post-CPB). The same anesthesiologist administered stan-
dardized total intravenous anesthesia using sufentanil, mida-
zolam, propofol and pancuronium.
Immediately before CPB, 300 IU/kg heparin was ad-
ministered intravenously, followed by additional doses as
necessary to maintain an activating clotting time exceeding
500 sec. Protamine was administered as 1 mg /100 IU of the
heparin dose after complete separation from CPB.
All the patients had CABG with the use of CPB, which
was conducted with a roller pump and a membrane oxy-
genator primed with a solution. During CPB, pump flow was
set at 2.4 times the body surface area, and mean arterial pres-
sure maintained between 50 mmHg and 60 mmHg. The tem-
perature was allowed to drift with active rewarming at the
end of CPB. Myocardial protection was afforded with cold
potassium cardioplegia. A single-clamp technique was used,
and cardioplegia was given in an anterograde fashion. In all
the patients, the left internal mammary artery harvested and
anastomosed to the left anterior descending artery. The rest
of the grafts were constructed using the great saphenous
vein.
After a total release of the aortic cross-clamp, epicardial
atrial or ventricular pacing wires were placed. Aortic and ve-
nous cannulas were removed after an appropriate test dose of
protamine, and the surgery proceeded with closure of the
pericardium and sternum.
After the surgery, the patients were followed up in the
Intensive Care Unit (ICU) and were weaned off mechanical
ventilation when they fulfilled the following criteria: hemo-
dynamic stability, peripheral temperature of more than 36 °C,
cooperatively, and no major bleeding.
Blood for hemoglobin (Hb) concentration, hematocrit
(Hct), platelet count and coagulation profile determination
including international normalised ratio (INR) and activated
partial thromboplastin time (aPTT), was taken from a radial
arterial catheter before start CPB and 2 h after arrival in the
ICU for all the patients in the two groups. Transfusion of
blood products and management of postoperative bleeding
intra- and postoperatively were determined by following in-
stitutional algorithm. Platelet function analysis was per-
formed using the multiple electrode aggregometry (multi-
plate-analyzer) before started CPB and 2 h after arrival in the
ICU for all the patients of both groups. The method has been
described in detail elsewhere 
14. Platelet aggregation was ini-
tiated using arachidonic acid (ASPI test), adenosine diphos-
phate (ADP test), thrombin receptor–activating peptide
(TRAP test) and collagen (COL test) using commercially
available test reagents. Increased impedance caused by at-
tachment of platelets to the test cell electrodes was continu-
ously measured over 6 min. Platelet aggregation was quanti-
fied as the area under the aggregation curve  [AUC(U)]. Ref-
erence ranges for healthy subjects obtained from the manu-
facturer were 79–141 U for the ASPI test, 41–99 U for the
ADP test,  92–151 U for the TRAP test, and 61–108 U for
COL test.
The results were presented as mean values with standard
deviation. The significance of differences betwen the study
groups was analyzed using the t-test. Due to great variability
of some data, the Wilcoxon matched pairs test and the Mann-
Whitney  U-test were also used. Comparison between more
than two groups was done by using the Kruskal-Wallis test.
A p-value less than 0.05 was taken to be significant.
The obtained data were processed through the Stat for Win-
dows, R.4.5. Software package.
Results
The results of the study are presented in Tables 1 to 3
dealing with baseline and operative characteristics of the pa-
tients (Table 1), the effect of CPB procedure on hematologi-
Table 1
Baseline and operative characteristics of the patients in the control and PUFAs group
Parameter Control group PUFAs group p
Age (years) 62.4 ± 7 65.3 ± 8 0.56
Gender (m/f) 18/2 17/3 0.36
Weight (kg) 89.8 ± 6 92.1 ± 5 0.48
Height (cm) 176.4 ± 4 178.5 ± 3 0.06
LVEF (%) 54 ± 6 53 ± 9 0.1
CPB (min) 101.4 ± 21 95.5 ± 17 0.29
Aortic cross-clamp time (min) 42.5 ± 9 38.9 ± 8 0.66
CABG (number) 2.9 ± 0.8 2.8 ± 0.7 0.65
Total heparin dose (units u 1,000) 27.7 ± 1.5 27.6 ± 2.2 0.86
Total protamin dose (mg) 279 ± 13 282 ± 19 0.638
Data presented as mean value ± standard deviation. PUFA – polyunsaturated fatty acids; LVEF – left ven-
tricular ejection fraction; CPB – cardiopulmonary bypass; CABG – coronary artery
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cal parameters (Table 2), the effect of CPB procedure on the
activity of platelets in the control and the PUFAs group of
patients (Table 3), and peri- and postoprative complications.
Table 1 shows that the baseline and operative charac-
teristics of the patients included in the study did not differ
between the control and the PUFAs group in any of the ob-
served parameters. This equally relates intraoperative CPB
(101.4 min vs 95.5 min; p = 0.29), aortic cross-clamp time
(42.5 min vs 38.9 min; p = 0.66), CABG number (2.9 min vs
2.8; p = 0.65) and total heparin use (27.7 min vs 27.6 units u
1,000; p = 0.86), and postoperative interventions: total pro-
tamine dose (279 mg vs 282 mg; p = 0.63).
Table 2 shows that hematological data regarding preop-
erative and on the arrival to ICU, as well as intraoperative
and postoperative requirements for allogenic RBCs, FFP and
platelet units were similar in both groups of patients, with no
statistically significant difference.
Regarding transfusion requirements and postoperative
blood loss, there were no statsitically significant differences
between the control and the PUFAs group in allogenic red
blood cells (RBCs) (1.9 vs 1.9; p = 0.94), fresh frozen
plasma (FFP) (1.9 vs 1.7; p = 0.52) and platelete (1.2 vs 1.35;
p = 0.73) units, as well as in postoperative blood loss (608 ±
210 mL vs 680 ± 274 mL, p = 0.356).
Table 3 shows that the level of platelet aggregation
reached the reference values in both groups of patients and in
all four performed tests, indicating thus their normal values.
In all instances, the observed values were above, but closer
Table 2
Hematological data in the patients subjected to CPB
Parameter Control
group
PUFAs
group p
Prior to operation
  hemoglobin (g/L) 134 ± 4.2 134  ± 3.2 0.535
  hematocrit (%) 38 ± 2.7 37 ± 2.4 0.628
  platelets (x10
9/L) 255 ± 42 259 ± 57 0.823
  INR 1.06 ± 0.03 1.08 ± 0.03 0.139
  aPTT (sec) 38.8 ± 3.9 39.6 ± 3.3 0.493
On arrival to ICU
  hemoglobin (g/L) 111 ± 8.3 109 ± 8.5 0.542
  hematocrit (%) 29 ± 6.9 29.4 ± 2.3 0.832
  platelets (u 10
9/L) 132 ± 34 129 ± 43 0.796
  INR 1.17 ± 0.07 1.18 ± 0.14 0.703
  aPTT (sec) 44.2 ± 4.5 45.8 ± 5.9 0.345
Transfusion requrements
Intraoperative
  allogenic RBCs (units) 1.3 ± 0.7 1.4 ± 0.8 0.738
  FFP (units) 0.5 ± 0.8 0.4 ± 0.8 0.946
  platelets (units) 0 0
Postoperative (0–24 h)
  allogenic RBC (units) 1.9 ± 0.7 1.9 ± 0.8 0.946
  FFP (units) 1.7 ± 1 1.9 ± 0.9 0.529
  platelets (units) 1.2 ± 1.3 1.35 ± 1.35 0.738
Postoperative blood loss 0–24 h (mL) 608 ± 210 680 ± 274 0.356
Data presented as mean value ± standard deviation. CPB – cardiopulmonary bypass; PUFA - polyunsaturated fatty acids; INR-international
normalization ratio; aPTT – activated partial thromboplasin time;   ICU – intensive care unit; RBC – red blood cells; FFP – fresh frozen plasma.
  Table 3
The influence of polyunsaturated fatty acids (PUFAs) on the platelet aggregation
in multiple electrode aggregometry
Area under curve (U), ʉ ± SD Parameter control group PUFAs group p
ADP test  (41–99 U)*
   preoperative 61.4 ± 20 57.8 ± 20 0.587
   postoperative 42.3 ± 15 39.4 ± 11 0.701
ASPI test (79–141 U)*
   preoperative 92.6 ± 23 90.2 ± 20 0.719
   postoperative 70.1 ± 27 64.9 ± 24 0.525
TRAP test (92–151 U)*
   preoperative 96.8 ± 23 95.4 ± 23 0.845
   postoperative 75.1 ± 26 68.1 ± 25 0.396
COL test (61–108)*
   preoperative 68.2 ± 17 64.4 ± 16 0.465
   postoperative 47.7 ± 20 32.3 ± 15 0.009
Data presented as mean value ± standard deviation. ADP – adenosine diphosphate; ASPI – arachidonic acid-induced platelet aggre-
gation; TRAP – thrombin receptor activating peptide; COL – collagen; *reference ranges for healthy subjects.Strana 400 VOJNOSANITETSKI PREGLED Volumen 70, Broj 4
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to the lower levels of aggregators reference potencies given
in the brackets.
The second part of the results concerns the intergroup
differences in the platelet aggregation pre-, and postopera-
tively. In that respect, almost all the tests showed equal ac-
tivity of plateletes before the surgical intervention in the PU-
FAs group in relation to the control group of patients. Post-
operatively, platelet aggregation was not significantly differ-
ent between the PUFAs and the control group in the ADP
test (39 ± 11 vs 42 ± 15; p = 0.701), ASPI test (64 ± 24 vs 70
± 27; p = 0.525) and TRAP test (68 ± 25 vs 75 ± 26; p =
0.396), while their aggregation in COL test was statistically
significantly lower in the PUFAs related to the control group
(32 ± 15 vs 47 ± 20; p = 0.009).
Postoperative complications were similar in both
groups of patients. In the control group, one patient died of
cardiac failure on the second postoperative day, two patients
had perioperative infarction, three patients needed inotropic
support. In the PUFAs group, one patient underwent reexplo-
ration for bleeding, one had a respiratory failure and two pa-
tients needed inotropic support. Due to the low number of
the observed complications, no statistical comparison was
performed.
Discussion
We studied the relatoinship between omega-3 PUFAs,
which may influence the activity of platelets, and the hema-
tological parameters liable to imapirment in patients with
CPB, and found that in spite of the marked decrease in the
postoperative activity of platelets, more pronounced in the
PUFAs group of patients in relation to placebo in the COL
test, they did not affect any of the observed intra- and post-
operative hematological parameters (blood loss, RBC, FFP
and platelet requirements).
Due to the separate study types, discussion is given in
two parts: the effect of CPB on hematological parameters,
and the influence of omega-3 PUFAs in CPB procedure on
the activity of platelets.
The effect of CPB on hematological parameters
Statistically significant differences were postoperatively
found in both groups of the studied patients in some hema-
tological parameters, like Hb and Htc levels and platelet
counts, but not in the others as INR and aPTT. This is very
important, since bleeding after cardiac surgery may ensue
either from surgical (anastomoses, sternum, cannulation
sites) or nonsurgical sites. If bleeding becomes excessive or
causes hemodynamic disorders, reexploraton of mediastinal
wound is necessary. In our study, one patient in the PUFAs
group underwent reexploration for bleeding. Studies from the
other authors have shown that reexploration can be associ-
ated with multiple negative outcomes such as renal failure,
sepsis, atrial fibrilation, prolonged mechanical ventilation
and hospital stay and, most notably, increased mortality and
costs 
1–4.
There have also been studies in which patients with
coronary bypass grafting 
15–17, endarterectomy 
18, 19, and
femoral artery catheterization 
20–22 were given omega-3 PU-
FAs. In these studies, identically with our results, the risk of
clinically significant bleeding was virtually nonexistant.
However, in this respect, one has to keep in mind the review
of Bays 
23 in which he concluded that although there is little
evidence for increased risk of clinically significant bleeding
with omega-3 PUFAs supplementation, clinicians should be
aware of this as a theoretical possibility.
The influence of omega-3 PUFAs in CPB procedure on
the activity of platelets
The results of our study show that preoperative activity
of platelets in both groups of patients were in the range of
reference values for all of the four used tests. Conversely,
after the surgical intervention, their activity was statistically
significantly reduced, with easily noticable lower values in
PUFAs group in relation to placebo, particularly in COL test.
This finding is very relevant, because platelets play an
important role in maintaining normal hemostatic function.
Their disfunction is a major cause of excessive bleeding in
the early postoperative period after CPB procedures 
24, 25, not
found in our patients. Transient impairment of platelet func-
tion is mediated by platelet activation during passage through
the synthetic, nonendothelial surface of the extracorporeal
circuit, used also in our patients with twofold decrease in
their count, and involves the secondary release and partial
depletion of Į-granules. Platelet dysfunction may also be re-
lated to other factors
 24. Hypothermia related CPB influences
platelet function and coagulation 
26, the effect which can per-
sist into the ICU 
27, and be more pronounced as the time on
CPB increases 
28, 29.
Multiple electrode platelet aggregometry (MEA) used
in our study, allows the assessment of platelet function with-
out centrifugation steps 
30, and has proven sensitive for
platelet inhibition induced by aspirin and clopidogrel, as well
as for the effects of CPB and of hypothermia on platelet ag-
gregation 
31–34. The test has also been found to be able to de-
tect impaired hemostasis after CPB surgery 
35–37 and to iden-
tify patients before and after cardiac surgery with enhanced
risk of bleeding and of blood transfusion 
38, 39.
The mechanism of favorable antithrombotic effects of
omega-3 PUFAs found in our study are complex. It has been
shown that alteration of fatty acid composition by omega-3
PUFAs incorporation into platelet membranes can alter not
only membrane permeability, but also modulate function and
activity of membrane receptors and transporters 
40, 41. The
COL test reagent, being the most sensitive in our study,
contains collagen, which activates the platelets by the colla-
gen receptor. Following its binding to the receptors, AA is
released, which is the substrate of platelet enzyme cyclooxy-
genase (COX). COX transforms AA into TXA2, a potent
platelet activator. With a blockade of COX, the formation of
TXA2 is inhibited and therefore inhibited platelet activation
is usually detected, as happened to be in our patients.
In most studies either no effect on platelet aggregation was
found with omega-3 fatty acids or no difference in effect was
seen between the treatments and the control. Kwon  et al. 
42
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platelet aggregation was found at three weeks on canola oil
diet, which reverted to baseline by eight weeks. Freese et
al. 
43 reported that the decrease in collagen-induced aggrega-
tion in the fish oil supplement arm did not return to baseline
during a 12 week follow-up period.
Overall, although there is heterogeneity among the
studies, there is a trend toward a net reduction of coronary
artery restenosis with fish oil supplementation, estimated by
the meta-analysis to lower such a risk for 14% 
21, 44. The op-
timal degree of platelet inhibition is unclear and must be con-
firmed in trials evaluating cardiovascular outcomes and
sould be balanced with the excessive risk of bleeding 
45. In
any case, the results of our study show that the postoperative
inhibition of platelet aggregation by PUFAs, particularly
pronounced in the COL test, did not affect the intra- and
postoperative hematological parameters, with the risk of
bleeding, as the most dangerous, being equal to the placebo
group. This finding undoubtedly speaks in favour of omega-
3 PUFAs use as cardioprotectors in patients with open heart
surgery, found in our recent study 
12.
Conclusion
The results of our study show that acute omega-3 PUFAs
pretreatment of patients subjected to CBP grafting did not af-
fect INR, aPTT and bleeding volume, while the postoperative
platelet count dropped twofold, equally in the PUFAs and pla-
cebo treated groups. The activity of platelets was statistically
significantly lower after surgical intervention in both groups of
patients, particularly markedly pronounced in the COL test in
the PUFAs group, but with no negative effect on bleeding.
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